Moreover, pharmacological reduction of JNK activity not only shifted Smad3 signaling from oncogenesis to tumor-suppression but also inhibited cell proliferation in MUC1-overexpressing HCC cells. Here, SMAD3 is linked to hepatocellular carcinoma.